Surfactant protein A enhances mycobacterial killing by rat macrophages through a nitric oxide-dependent pathway

Am J Physiol Lung Cell Mol Physiol. 2000 Aug;279(2):L216-23. doi: 10.1152/ajplung.2000.279.2.L216.

Abstract

Surfactant-associated protein A (SP-A) is involved in surfactant homeostasis and host defense in the lung. We have previously demonstrated that SP-A specifically binds to and enhances the ingestion of bacillus Calmette-Guerin (BCG) organisms by macrophages. In the current study, we investigated the effect of SP-A on the generation of inflammatory mediators induced by BCG and the subsequent fate of ingested BCG organisms. Rat macrophages were incubated with BCG in the presence and absence of SP-A. Noningested BCG organisms were removed, and the release of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide were measured at varying times. TNF-alpha and nitric oxide production induced by BCG were enhanced by SP-A. In addition, SP-A enhanced the BCG-induced increase in the level of inducible nitric oxide synthase protein. Addition of antibodies directed against SPR210, a specific macrophage SP-A receptor, inhibited the SP-A-enhanced mediator production. BCG in the absence of SP-A showed increased growth over a 5-day period, whereas inclusion of SP-A dramatically inhibited BCG growth. Inhibition of nitric oxide production blocked BCG killing in the presence and absence of SP-A. These results demonstrate that ingestion of SP-A-BCG complexes by rat macrophages leads to production of inflammatory mediators and increased mycobacterial killing.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies / pharmacology
  • BCG Vaccine / immunology
  • Benzothiazoles
  • Blotting, Western
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Female
  • Macrophages / cytology
  • Macrophages / drug effects
  • Macrophages / metabolism*
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / immunology*
  • Mycobacterium tuberculosis / metabolism
  • Nitric Oxide / metabolism*
  • Nitric Oxide / pharmacology
  • Nitric Oxide Synthase / biosynthesis
  • Nitric Oxide Synthase Type II
  • Proteolipids / metabolism*
  • Proteolipids / pharmacology
  • Pulmonary Surfactant-Associated Protein A
  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants / metabolism*
  • Pulmonary Surfactants / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Thiazines / antagonists & inhibitors
  • Thiazines / metabolism
  • Thiazoles / antagonists & inhibitors
  • Thiazoles / metabolism
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Uracil / metabolism
  • omega-N-Methylarginine / pharmacology

Substances

  • Antibodies
  • BCG Vaccine
  • Benzothiazoles
  • Enzyme Inhibitors
  • Proteolipids
  • Pulmonary Surfactant-Associated Protein A
  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants
  • Thiazines
  • Thiazoles
  • Tumor Necrosis Factor-alpha
  • SPR 210
  • omega-N-Methylarginine
  • Nitric Oxide
  • Uracil
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat